<DOC>
	<DOCNO>NCT00993525</DOCNO>
	<brief_summary>To evaluate fluorescein angiographic visual acuity effect single intravitreal injection ranibizumab management persistent new vessel associate diabetic retinopathy .</brief_summary>
	<brief_title>Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy ( Inipe Study )</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>persistent new vessel , define fine retinal vessel dilate bud tip cover hemorrhage associate recurrent vitreous hemorrhage paucity accompany fibrous tissue and/or increase extent compare previous visit , unresponsive complete panretinal laser photocoagulation perform least 4 month prior ; logarithm minimum angle resolution ( logMAR ) bestcorrected visual acuity 0.17 ( Snellen equivalent , 20/30 ) bad . history vitrectomy study eye ; history thromboembolic event ( include myocardial infarction cerebral vascular accident ) ; major surgery within prior 6 month plan within next 28 day ; uncontrolled hypertension ; know coagulation abnormality current use anticoagulative medication aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>new vessel</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>Persistent retina new vessel</keyword>
</DOC>